hookipa
pharma
report
third
quarter
financial
results
november
new
york
vienna
austria
globe
newswire
hookipa
pharma
nasdaq
hook
hookipa
company
developing
new
class
immunotherapeutics
based
proprietary
arenavirus
platform
today
announced
release
financial
results
third
quarter
ended
september
market
opens
thursday
november
company
conducting
conference
call
conjunction
earnings
release
otherwise
noted
company
conduct
earnings
conference
call
conjunction
fourth
quarter
earnings
releases
hookipa
hookipa
pharma
nasdaq
hook
clinical
stage
biopharmaceutical
company
developing
new
class
immunotherapeutics
based
proprietary
arenavirus
platform
reprograms
body
immune
system
hookipa
proprietary
technologies
replicating
induce
robust
cells
antibodies
hookipa
viral
vectors
target
antigen
presenting
cells
vivo
activate
immune
system
technologies
enable
repeat
administration
augment
refresh
immune
responses
monotherapy
replicating
arenavirus
technology
potential
induce
cell
response
levels
previously
achieved
approaches
hookipa
prophylactic
cytomegalovirus
cmv
vaccine
candidate
currently
phase
clinical
trial
patients
awaiting
kidney
transplantation
expand
infectious
disease
portfolio
hookipa
entered
collaboration
licensing
agreement
gilead
sciences
research
functional
cures
hiv
chronic
hepatitis
b
infections
addition
hookipa
building
proprietary
pipeline
targeting
virally
mediated
cancer
antigens
antigens
lead
replicating
arenavirus
oncology
product
candidates
development
treatment
human
papilloma
virus
cancers
phase
clinical
trial
find
hookipa
online
